Mesoblast Signs Deal In China For Stem Cell Heart Therapies [Seeking Alpha]
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: Seeking Alpha
Summary Mesoblast Limited ( MESO ) announced yesterday that it had entered into a partnership with China based Tasly Pharmaceutical Group . The deal gives Tasly exclusive rights in China for Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM for the indications of Chronic Heart Failure (CHF) and MPC-25-IC for Acute Myocardial Infarction, a.k.a, heart attack. Mesoblast is currently running two Phase III trials in the U.S. for CHF as indicated in the pipeline below from Mesoblast’s website: Under the agreement Mesoblast will receive $40,000,000 up front. $20,000,000 as a technology access fee and another $20,000,000 for the purchase of its Australian shares at a price representing a 20% premium to a blended volume weighted average price calculated over three months, one month and one day. Some of the other terms are: Tasly will receive exclusive rights and will fund all development, manufacturing and commercialization activ
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Three Leading Growth Companies In Australia With Insider Ownership Reaching 27% [Yahoo! Finance]Yahoo! Finance
- Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]Yahoo! Finance
- Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]Yahoo! Finance
- Mesoblast Limited: Back From The Dead [Seeking Alpha]Seeking Alpha
- Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat